Muscle & Aging

What Do Growth Hormone Secretagogues Actually Do?

The short answer

Ipamorelin and CJC-1295 have never been tested in a human trial for muscle, strength, or aging outcomes — the only completed clinical trials of these two compounds studied gut motility after bowel surgery. A related GHRH analog, studied in 19 adults aged 55-71 over 5 months, raised IGF-1 and increased lean body mass, insulin sensitivity, and libido — but only in men, not women. Another secretagogue, MK-677, raised IGF-1 by up to 73% over 12 months in a 563-person Alzheimer's trial, yet produced no measurable clinical benefit on any outcome tested. The pattern across this drug class is consistent: these compounds reliably move growth hormone and IGF-1 blood levels. What that does for muscle in aging humans, specifically, is mostly untested or unproven.

Quick answers

What is it?
Growth hormone secretagogues (ipamorelin, CJC-1295, sermorelin, MK-677, tesamorelin) are compounds that stimulate the body's own release of growth hormone rather than supplying it directly.
Why are people interested in it?
These are widely marketed for muscle-building and anti-aging, so people want to know if any human trial actually tested them for that purpose.
What has actually been studied?
Registered human trials of each compound (gut motility, HIV lipodystrophy, osteoporosis, Alzheimer's disease), a 5-month trial of a related GHRH analog in older adults, and a 2008 563-person Alzheimer's trial of MK-677 tracking IGF-1 and clinical outcomes.
How strong is the evidence?
Very thin for muscle/anti-aging use: ipamorelin and CJC-1295 have never been tested in a human trial for muscle or aging outcomes, and even MK-677, tested most extensively, raised IGF-1 substantially with zero measurable clinical benefit in its largest trial.
What don't we know yet?
Whether ipamorelin or CJC-1295 do anything for muscle in humans at all, why GHRH analog benefits appeared in men but not women in one trial, whether raising IGF-1 translates into functional benefit in aging adults, and long-term safety for healthy adults using these off-label.
Where can I read the original research?
Sources at the bottom of this page: Khorram O, Laughlin GA, Yen SS, The Journal of Clinical Endocrinology and Metabolism, 1997; and Sevigny JJ, Ryan JM, van Dyck CH, et al., Neurology, 2008.
Explainer · every figure sourced on screen

The short answer: Ipamorelin and CJC-1295 have never been tested in a human trial for muscle, strength, or aging outcomes — the only completed clinical trials of these two specific compounds studied gastrointestinal motility after bowel surgery. A related growth hormone-releasing hormone (GHRH) analog, studied in 19 adults aged 55 to 71 over 5 months, raised IGF-1 levels and increased lean body mass, insulin sensitivity, and libido — but only in the men in the study, not the women. Another oral secretagogue, MK-677, raised IGF-1 by as much as 73% over 12 months in a 563-person Alzheimer's disease trial, yet produced no measurable clinical benefit on any outcome tested. Across this drug class, the pattern is consistent: these compounds reliably move growth hormone and IGF-1 blood levels. What that does for muscle in aging humans, specifically, is mostly untested or unproven.

Explainer · every figure sourced on screen

What the research shows

Ipamorelin and CJC-1295: real drugs, but not tested for this

Ipamorelin and CJC-1295 are both growth hormone secretagogues — compounds designed to stimulate the body's own release of growth hormone, rather than supplying it directly. Both have been through registered human clinical trials. But a search of those trials shows the indications tested have nothing to do with muscle or anti-aging use. Ipamorelin has been studied in placebo-controlled trials for recovery of gastrointestinal function after bowel resection surgery (320 participants) and for post-operative ileus (117 participants). CJC-1295 was tested in a multicenter trial for HIV-associated visceral obesity, enrolling 120 participants — a trial that was ultimately terminated. None of these trials measured muscle mass, strength, or a body-composition outcome relevant to aging-related muscle loss.

A 2026 review in The American Journal of Sports Medicine, searching specifically for musculoskeletal evidence on CJC-1295 combined with ipamorelin, found the combination "significantly improved maximum tetanic tension" — a measure of muscle contractile force — in mice with glucocorticoid-induced muscle loss. The reviewers were explicit that "these findings are limited to animal studies." No human trial testing this combination for muscle has been identified.

Sermorelin and related GHRH analogs: real trials, sex-specific and modest results

Sermorelin belongs to a related class: analogs of growth hormone-releasing hormone (GHRH), the natural signal that triggers the pituitary gland to release growth hormone. One of the few placebo-controlled human trials in this space tested a closely related GHRH analog — [Nle27]GHRH-(1-29)-NH2 — in 19 adults aged 55 to 71 (10 women, 9 men) over 5 months. Nightly injections increased 12-hour nocturnal GH and IGF-1 within two weeks. But on body composition and metabolic outcomes, the benefits split sharply by sex: lean body mass, insulin sensitivity, and general well-being and libido all improved significantly in men (P<0.05 or better) but not in women. Skin thickness increased in both sexes; body weight and bone density changed in neither. The authors concluded the GHRH analog "induced anabolic effects favoring men more than women" and called for research to explain why.

MK-677: the clearest illustration of the biomarker-outcome gap

MK-677 (ibutamoren) is an orally active growth hormone secretagogue studied more extensively in humans than most compounds in this class, across several small-to-mid-sized trials from the 1990s through the 2000s. In 32 healthy elderly adults aged 64 to 81, four weeks at 25 mg/day increased mean IGF-1 from 141 µg/L at baseline to 265 µg/L — into the range typical of young adults — while also raising fasting glucose. In 24 obese men, 8 weeks significantly increased fat-free mass on DXA (P<0.01), though visceral fat didn't change and an early rise in metabolic rate faded by week 8. In 292 postmenopausal women with osteoporosis, adding MK-677 to alendronate increased bone density at the femoral neck (4.2% vs. 2.5% with alendronate alone, P<0.05) — but not at the spine, hip, or total body.

The largest and most rigorous test of MK-677 was a 2008 randomized trial in 563 patients with mild-to-moderate Alzheimer's disease, run over 12 months because IGF-1 had been linked in animal research to clearance of amyloid protein from the brain. MK-677 increased serum IGF-1 by 60.1% at 6 weeks and 72.9% at 12 months — a substantial, sustained effect. But on every clinical measure tracked — impression of change, cognitive score, activities-of-daily-living scale, dementia rating — there was no significant difference from placebo. The IGF-1 axis moved; nothing that mattered to patients moved with it.

Tesamorelin: real muscle-relevant data, in a different population

Tesamorelin, another GHRH analog, has substantially more human trial data than the others discussed here, because it was developed and approved specifically for HIV-associated lipodystrophy. A systematic review of 10 placebo-controlled trials totaling 1,511 participants with that condition found growth hormone axis treatments, tesamorelin included, decreased visceral fat and increased lean body mass by a weighted mean of 1.31 kg (95% CI: 1.00–1.61 kg, P<0.001) versus placebo. That's real, replicated human evidence of a lean-mass effect — but from a population with HIV-related fat redistribution, not otherwise-healthy older adults losing muscle to age.

What we don't know yet

Whether ipamorelin or CJC-1295 do anything for muscle in humans at all. No human trial of either compound has measured a muscle strength, mass, or function outcome; the entire evidence base for their muscle effects is a single mouse study of the combination.

Why GHRH analog effects on lean mass appeared in men but not women in the one aging-focused trial that tested both sexes — the mechanism behind that sex difference has not been established.

Whether raising IGF-1 through a secretagogue translates into any functional benefit in aging adults specifically. The largest, most rigorous trial of this drug class (MK-677 in Alzheimer's disease) found a large biomarker change with zero measurable clinical benefit, which raises the question of whether IGF-1 elevation is a meaningful surrogate for muscle or functional outcomes in older adults generally.

What the long-term safety profile looks like for healthy aging adults using these compounds off-label. The trials reviewed here were short (weeks to about a year), used clinical populations (Alzheimer's patients, osteoporotic women, people with HIV lipodystrophy) rather than healthy older adults, and were not designed to detect rare or long-latency harms.

Whether tesamorelin's lean-mass benefit in HIV-associated lipodystrophy generalizes to age-related muscle loss in people without that condition. This specific comparison has not been tested.

Sources

  1. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of Clinical Endocrinology and Metabolism, 1997;82(5):1472-1479. DOI
  2. Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008;71(21):1702-1708. DOI
  3. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. The Journal of Clinical Endocrinology and Metabolism, 1996;81(12):4249-4257. DOI
  4. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. The Journal of Clinical Endocrinology and Metabolism, 1998;83(2):362-369. DOI
  5. Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. The Journal of Clinical Endocrinology and Metabolism, 2001;86(3):1116-1125. DOI
  6. Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine, 2026;54(1):223-229. DOI
  7. Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American Journal of Sports Medicine, 2026. DOI
  8. Sivakumar T, Mechanic OJ, Fehmie DA, Paul BT. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Medicine, 2011;12(8):453-462. DOI

Article records maintained via PubMed and ClinicalTrials.gov. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.

Topic: Energy & Performance · Aging & Longevity  |  Evidence Index: ipamorelin · cjc-1295 · sermorelin · mk-677 · tesamorelin

Sources

Endocrine and Metabolic Effects of Long-Term Administration of [Nle27]Growth Hormone-Releasing Hormone-(1-29)-NH2 in Age-Advanced Men and Women
The Journal of Clinical Endocrinology and Metabolism, 1997 · n=19 · DOI
Growth Hormone Secretagogue MK-677: No Clinical Effect on AD Progression in a Randomized Trial
Neurology, 2008 · n=563 · DOI
Stimulation of the Growth Hormone (GH)-Insulin-Like Growth Factor I Axis by Daily Oral Administration of a GH Secretagogue (MK-677) in Healthy Elderly Subjects
The Journal of Clinical Endocrinology and Metabolism, 1996 · n=32 · DOI
Two-Month Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure
The Journal of Clinical Endocrinology and Metabolism, 1998 · n=24 · DOI
Effect of Alendronate and MK-677, Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women
The Journal of Clinical Endocrinology and Metabolism, 2001 · n=292 · DOI
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
The American Journal of Sports Medicine, 2026 · DOI
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
The American Journal of Sports Medicine, 2026 · DOI
Growth Hormone Axis Treatments for HIV-Associated Lipodystrophy: A Systematic Review of Placebo-Controlled Trials
HIV Medicine, 2011 · n=1511 · DOI

More in Muscle & Aging

Do collagen peptides do anything for muscle mass, strength, or joint pain?Do Collagen Peptides Do Anything for Muscle or Joints?Does BPC-157 do anything for muscle healing or growth in humans?Does BPC-157 Do Anything for Muscle?Does creatine supplementation still work for muscle strength and mass after age 50?Does Creatine Still Work After 50?